Contravir Pharmaceuticals, Inc.

NASDAQ: CTRVHealthcare / Biotechnology / USA
4.74-0.5600-10.57%Vol 1 034 5171Y Perf -95.66%
Jun 19th, 2019 16:00
BID4.70 ASK4.75
Open5.09 Previous Close5.30
Pre-Market4.90 After-Trading4.80
 0.16 3.38%  0.06 1.27%
Target Price
2.00 
Analyst Rating
Hold 3.00
Potencial %
-57.81 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
-/-/- 
Income Ranking
 —    -
Market Cap (mil)3 
Earnings Rating
Neutral
Price Range Ratio 52wk %
0.11 
Earnings Date
23rd May 2018

Today's Price Range

4.625.28

52wk Range

4.62117.60

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Month
3 850.00%
3 Months
1 655.56%
6 Months
1 429.03%
1 Year
-95.66%
3 Years
-36.97%
5 Years
-65.15%

Name / TickerPriceChg.Chg.%
CTRV4.74-0.5600-10.57
AAPL197.87-0.5800-0.29
GOOG1 102.33-1.2700-0.12
MSFT135.690.53000.39
XOM75.32-0.4200-0.55
WFC45.65-0.4500-0.98
JNJ140.450.22000.16
FB187.48-0.9900-0.53
GE10.33-0.0900-0.86
JPM109.91-0.8000-0.72
Earnings HistoryEstimateReportedSurprise %
Q03 2018--0.03-
Q03 2017-0.14-0.0842.86
Q02 2017-0.14-0.1121.43
Q01 2017-0.14-0.137.14
Q04 2016-0.15-0.16-6.67
Q03 2016-0.23-0.1439.13
Q02 2016-0.25-0.2020.00
Q03 2015-0.15-0.33-120.00
Earnings Per EndEstimateRevision %Trend
6/2017 QR-0.090.00-
6/2017 QR-0.140.00-
6/2018 FY-0.410.00-
6/2018 FY-0.410.00-
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume1 034 517
Shares Outstanding (in ths.)730
Trades Count3 522
Dollar Volume4 578 769
Avg. Volume271 920
Avg. Weekly Volume2 285 124
Avg. Monthly Volume1 448 589
Avg. Quarterly Volume494 231
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0 (0.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (100.00 %)
1 (100.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingHold
3.00
Hold
3.00
Strong Buy
1.00

Contravir Pharmaceuticals, Inc.

ContraVir Pharmaceuticals Inc is a United States-based biopharmaceutical company engaged in the development of targeted pharmaceutical therapies for liver disease. The company focuses on developing two novel oral compounds to treat HBV infection. CRV431 is a cyclophilin inhibitor that targets specific isomerases that play an important role in protein folding in health and in disease. TXL is a nucleotide pro-drug of tenofovir that inhibits hepatitis B viral replication and targets the liver, the reservoir for the hepatitis B virus.

CEO: Robert T. Foster

Teplephone: +1 732 902-4000

Address: 399 Thornall Street, First Floor, Edison 08837, NJ, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

49%51%

Bearish Bullish

65%35%

News